Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: A retrospective analysis of acute skin toxicity and dose inhomogeneities

63Citations
Citations of this article
82Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: To identify predictive factors of radiation-induced skin toxicity in breast cancer patients by the analysis of dosimetric and clinical factors.Methods: 339 patients treated between January 2007 and December 2010 are included in the present analysis. Whole breast irradiation was delivered with Conventional Fractionation (CF) (50Gy, 2.0/day, 25 fractions) and moderate Hypofractionated Schedule (HS) (44Gy, 2.75Gy/day, 16 fractions) followed by tumour bed boost. The impact of patient clinical features, systemic treatments and, in particular, dose inhomogeneities on the occurrence of different levels of skin reaction has been retrospectively evaluated.Results: G2 and G3 acute skin toxicity were 42% and 13% in CF patients and 30% and 7.5% in HS patients respectively. The retrieval and revaluation of 200 treatment plans showed a strong correlation between areas close to the skin surface, with inhomogeneities >107% of the prescribed dose, and the desquamation areas as described in the clinical records.Conclusions: In our experience dose inhomogeneity underneath G2 - G3 skin reactions seems to be the most important predictor for acute skin damage and in these patients more complex treatment techniques should be considered to avoid skin damage. Genetic polymorphisms too have to be investigated as possible promising candidates for predicting acute skin reactions. © 2013 Tortorelli et al.; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Tortorelli, G., Di Murro, L., Barbarino, R., Cicchetti, S., di Cristino, D., Falco, M. D., … Santoni, R. (2013). Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: A retrospective analysis of acute skin toxicity and dose inhomogeneities. BMC Cancer, 13. https://doi.org/10.1186/1471-2407-13-230

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free